ArticleAnalytical and bioanalytical chemistry2026
Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag-Au ternary nanocomposite.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) is a key biomarker associated with breast cancer, and its reliable detection using effective diagnostic tools is clinically significant. Here, we developed an electrochemical aptasensor based on an electroactive labeling strategy for the detection of HER2 using differential pulse voltammetry (DPV). A nickel nanofoam/gold nanoparticles (AuNPs)/silver nanoparticles (AgNPs) nanocomposite was employed as a novel electrode modifier synthesized via a simple, low-cost, and reproducible method. In this design, AuNPs enabled stable aptamer immobilization, while AgNPs acted as electroactive labels, enhancing the current response through a synergistic effect that could not be achieved with either nanoparticle alone. The newly developed aptasensor demonstrated high sensitivity and good reproducibility for HER2 detection. The aptasensor showed a wide linear range of 0.001-100 ng mL
Indexed as
Identifiers
41413339What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.